Array BioPharma

The Company’s wholly owned clinical stage drugs include Filanesib in Phase II clinical trials, is indicated for Kinesin spindle protein (KSP), inhibitor for MM; ARRY-797 in Phase II clinical trials, indicated for p38 inhibitor for Lamin A/C-related dilated cardiomyopathy (LMNA-DCM); ARRY-502 in Phase II clinical trials, indicated for CRTh2 antagonist for asthma, and ARRY-614 in Phase I clinical trials, is indicated for p38/Tie2 dual inhibitor for myelodysplastic syndromes (MDS). In addition, the Company has 11 ongoing partner-funded clinical programs, including two MEK inhibitors, which are both in Phase III clinical trials, binimetinib with Novartis and selumetinib with AstraZeneca.

Type
Public
HQ
Boulder, US
Founded
1998
Size (employees)
177 (est)+14%
Array BioPharma was founded in 1998 and is headquartered in Boulder, US

Array BioPharma Office Locations

Array BioPharma has offices in Boulder, Cambridge, Morrisville, Houston and in 7 other locations
Boulder, US (HQ)
3200 Walnut St
Morrisville, US
115 3005 Carrington Mill Blvd
Cambridge, US
301 125 Cambridge Park Dr
Show all (11)

Array BioPharma Data and Metrics

Array BioPharma Financial Metrics

Array BioPharma's revenue was reported to be $33.3 m in Q3, 2017
USD

Revenue (Q3, 2017)

33.3 m

Net income (Q3, 2017)

(35.3 m)

EBIT (Q3, 2017)

(31.9 m)

Market capitalization (21-Jul-2017)

1.4 b

Cash (30-Jun-2016)

56.6 m
Array BioPharma's current market capitalization is $1.4 b.
USDFY, 2014FY, 2015FY, 2016

Revenue

42.1 m51.9 m137.9 m

Revenue growth, %

23%166%

Gross profit

(3.9 m)7.5 m

Gross profit Margin, %

(9%)14%

Operating expense total

117.7 m130.3 m220.1 m

EBIT

(75.6 m)3.3 m(82.2 m)

EBIT margin, %

(180%)6%(60%)

Net Income

(85.3 m)9.4 m(92.8 m)
USDQ1, 2014Q2, 2014Q3, 2015Q1, 2015Q2, 2015Q3, 2016Q1, 2016Q2, 2016Q3, 2017

Revenue

35.4 m43 m39.3 m44.5 m33.3 m

General and administrative expense

9.9 m8.4 m7.9 m8.8 m11.7 m

Operating expense total

9.9 m8.4 m7.9 m8.8 m11.7 m

EBIT

(21.5 m)(20 m)(24 m)(19.8 m)(31.9 m)

EBIT margin, %

(61%)(46%)(61%)(44%)(96%)

Interest expense

(2.7 m)(2.7 m)(3 m)(3.1 m)(3.1 m)

Interest income

51 k76 k70 k212 k228 k

Net Income

(27.6 m)(36.2 m)22.1 m(21 m)(24.2 m)(22.7 m)(28.6 m)(23.3 m)(35.3 m)
USDFY, 2014FY, 2015FY, 2016

Cash

68.6 m55.7 m56.6 m

Accounts Receivable

5.4 m6.3 m39.3 m

Inventories

5.2 m6.4 m6.1 m

Current Assets

121.7 m191 m155.3 m

PP&E

8.2 m5.1 m6.7 m

Total Assets

139.1 m198.2 m168.9 m

Accounts Payable

7 m4.6 m10.1 m

Current Liabilities

52.7 m42.4 m52.4 m

Non-Current Liabilities

112 m113.1 m154.4 m

Total Liabilities

164.8 m155.6 m206.8 m

Additional Paid-in Capital

652.7 m711.7 m763.3 m

Retained Earnings

(717.9 m)(708.6 m)(801.4 m)

Total Equity

(25.7 m)42.7 m(37.9 m)

Financial Leverage

-5.4 x4.6 x-4.5 x
USDQ1, 2014Q2, 2014Q3, 2015Q1, 2015

Cash

46.8 m68.1 m141.5 m56.4 m

Accounts Receivable

6 m4.9 m2.1 m13.5 m

Current Assets

122.8 m150.8 m196.6 m179.6 m

PP&E

7.8 m8.1 m7.5 m5 m

Total Assets

135.3 m163.6 m208.4 m186.8 m

Accounts Payable

5.2 m9.3 m7.6 m6.5 m

Current Liabilities

56.6 m67.9 m44.9 m49.3 m

Non-Current Liabilities

116.3 m109.6 m113.4 m113.4 m

Additional Paid-in Capital

653.9 m687.2 m696.7 m753.5 m

Retained Earnings

(745.5 m)(754.1 m)(695.8 m)(729.6 m)

Total Equity

(37.6 m)(13.9 m)50.2 m24.1 m

Financial Leverage

-3.6 x-11.8 x4.2 x7.7 x
USDFY, 2014FY, 2015FY, 2016

Net Income

(85.3 m)9.4 m(92.8 m)

Depreciation and Amortization

4.5 m3.7 m1.5 m

Accounts Receivable

4.2 m(7.6 m)(33 m)

Cash From Operating Activities

(71.7 m)(5.8 m)(70.1 m)

Purchases of PP&E

(2.6 m)(2.5 m)(3.2 m)

Cash From Investing Activities

2.5 m66 m

Cash From Financing Activities

77.1 m50.9 m5 m

Interest Paid

4.3 m4.5 m4.5 m
USDQ1, 2014Q2, 2014Q3, 2015Q1, 2015Q2, 2015Q3, 2016Q1, 2016Q2, 2016Q3, 2017

Net Income

(27.6 m)(36.2 m)22.1 m(21 m)(24.2 m)(22.7 m)(28.6 m)(23.3 m)(35.3 m)

Depreciation and Amortization

876 k1.8 m2.8 m473 k

Accounts Receivable

(571 k)551 k(3.4 m)(7.2 m)64.8 m62.9 m33.9 m43.1 m32.5 m

Accounts Payable

12.1 m15.6 m5.9 m6.5 m7.8 m

Cash From Operating Activities

(18.8 m)(16.8 m)21.5 m(19.2 m)

Purchases of PP&E

(483 k)(1.7 m)(2.1 m)(411 k)

Cash From Investing Activities

(3 m)(15 m)

Cash From Financing Activities

45 k31.3 m38.8 m664 k

Interest Paid

121 k2.2 m2.3 m121 k
USDY, 2017

Revenue/Employee

188 k

Array BioPharma Market Value History

Array BioPharma Job Categories

Array BioPharma Company Life and Culture

You may also be interested in